Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Wall Street Analyst Weigh In
Several research firms have commented on SAVA. HC Wainwright reissued a "buy" rating on shares of Cassava Sciences in a research note on Thursday, August 4th. B. Riley lowered their target price on shares of Cassava Sciences from $58.00 to $44.00 and set a "buy" rating on the stock in a research note on Thursday.
Cassava Sciences Stock Performance
Shares of NASDAQ:SAVA traded up $0.57 during trading hours on Friday, hitting $20.42. 1,350,242 shares of the company's stock traded hands, compared to its average volume of 2,239,504. Cassava Sciences has a 52 week low of $13.84 and a 52 week high of $124.80. The company's fifty day simple moving average is $24.05 and its two-hundred day simple moving average is $29.90.